Clene Inc. announced positive results from a new analysis of the HEALEY ALS Platform Trial data. The analysis showed that CNM-Au8® 30 mg significantly improved survival in ALS patients, particularly those with moderate to severe disease and those meeting the criteria for Clene’s upcoming Phase 3 RESTORE-ALS trial. The results support earlier findings from the HEALEY trial, the Phase 2 RESCUE-ALS trial, and Expanded Access Programs, all suggesting a survival benefit with CNM-Au8 treatment compared to historical controls.
This news is potentially groundbreaking for ALS patients, who currently face limited treatment options and a devastating prognosis. The observed survival benefit, especially the substantial extension observed in specific patient subgroups, offers a glimmer of hope for improved outcomes and quality of life. These findings could reshape the ALS treatment landscape if confirmed in the upcoming Phase 3 trial.
The analysis compared CNM-Au8 30 mg to Regimen A of the HEALEY trial. Across the full analysis set, median survival increased by 6.5 months and restricted mean survival time (RMST) improved by 4.1 months. In a subset of patients with moderate to severe ALS, median survival increased by 11.9 months, with a 44% reduction in mortality risk. The most dramatic benefit was seen in patients meeting the RESTORE-ALS criteria, where median survival increased by 14.8 months and mortality risk decreased by 49%.
The positive results from this new analysis strengthen the rationale for the upcoming Phase 3 RESTORE-ALS trial. This trial is crucial for confirming the efficacy and safety of CNM-Au8, potentially paving the way for regulatory approval and widespread availability of this promising therapy. If the Phase 3 trial replicates these findings, CNM-Au8 could become a cornerstone of ALS treatment, significantly altering the disease trajectory for many patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
